Dole plc Ordinary Shares (DOLE)
Live price chart, market sentiment, and community perspectives for Dole plc (NYSE: DOLE).
Live price chart, market sentiment, and community perspectives for Dole plc (NYSE: DOLE).
Looking at the institutional ownership data for DOLE, we see 189 tracked 13F filers holding a combined $756.0 million. With 38 funds adding positions versus 20 trimming during the quarter, the smart-money sentiment leans moderately bullish, even as the stock trades near its 52-week range of $12.68 to $16.37.
On our desk, we are closely monitoring the segment dynamics following Q2 2026. While the Diversified Fresh Produce - Americas and ROW segment showed strong performance, it was partially offset by lower results in Fresh Fruit driven by anticipated cost pressures. Navigating these inputs will dictate near-term multiple expansion.
In our clinical practice, we observe patients increasingly integrating fresh produce due to broader health trends and dietary shifts associated with GLP-1 adoption. Dole’s explicit mention of GLP-1 adoption supporting consumer demand across their key markets validates this secular shift from a fundamental equity research standpoint.
As a hedge fund portfolio manager, I find Dole’s portfolio reshaping compelling. The recent completion of the Ecuador port sale yielding approximately $95 million in net proceeds, alongside the Greenfood Fresh Produce division acquisition in Scandinavia, demonstrates disciplined capital allocation and continuous asset optimization.
From a quantitative risk management perspective, DOLE's valuation needs to account for the structural portfolio changes executed over the past year, including the 2025 sale of the Fresh Vegetables division for roughly $140 million which is now reported under discontinued operations. Comparing year-over-year top-line figures requires adjusting for these perimeter shifts.
Tracking the options and price action down at $12.98, the stock reflects broader materials sector volatility. However, with Q1 net income printing at $37.7 million and diluted EPS at $0.33 alongside an Adjusted EBITDA of $100.3 million, the core operating cash generation remains stable despite cost headwinds.
Explore plasma cleansing, somatic organ swaps, and BCI.